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O-H.01 PANCREATIC FISTULAS AFTER
PANCREATICO-DUODENECTOMIES:
ARE PANCREATICO-GASTROSTOMIES
SAFER THAN
PANCREATICOJEJUNOSTOMIES? A
QUASI-EXPERIMENT AND
PROPENSITY-SCORE ADJUSTED
ANALYSIS
J. Abou Khalil, S. Dumitra, M. Jamal, N. Mayo,
P. Chaudhury, P. Metrakos and J. Barkun
McGill University Health Centers, Montreal, QC
Background: Pancreatic fistula (PF) is a major contributor
to morbidity and mortality after pancreaticoduodenectomy
(PD). There remains a debate as to whether reestablishing
pancreaticoenteric continuity through a Pancreatico-
Gastrostomy (PG,) compared to a Pancreatico-Jejunostomy
(PJ,) can decrease the risk of PF and total complications
GOAL We compared surgical outcomes of PG and PJ after
PD at our institution, where patient assignment to PG or PJ is
consistent with a Quasi-Experiment.
Methods: Data on pre-operative factors and post-operative
complications was collected for patients undergoing PD
between 1999 and 2011. We performed propensity-score
adjusted logistic regression to identify the effect of PG on
outcomes of PF, delayed gastric emptying (DGE), and total
complications. We used both ISGPF and Strasberg and
Linehan definition for PF and the ISGPS definition for DGE.
Total morbidity was assessed using the Clavien-Dindo clas-
sification and the Comprehensive Comorbidity Index (CCI).
Results: 23/103 and 20/103 (p = 0.49) of patients had PF
and 74/103 and 55/103 patients had all-grades DGE in the
PG and PJ groups respectively (p = 0.02). Groups did not
differ with regards to Clavien-Dindo grade (p = 0.29) but did
differ with regards to the CCI (38.4 vs. 31.4 for PG vs. PG
respectively p = 0.02.) Propensity-score adjusted multivari-
ate analysis showed no effect of surgical technique on PF
(p = 0.89), DGE grades B/C (p = 0.9) or CCI (p = 0.41) but
there remained an effect on all-grades DGE (p = 0.012).
Conclusion: Patients undergoing PG did not have less PF or
total complications than those reconstructed with PJ after PD
at our institution; odds of all-grade DGE were higher with
PG.
O-H.02 A NOVEL ONCOLYTIC
ADENOVIRUS TARGETING C-MET
RECEPTOR INCREASES INFECTIVITY
EFFICIENCY AND ONCOLYTIC
ACTIVITY IN HUMAN PANCREATIC
ADENOCARCINOMA CELL LINES
Q. D. Chu, G. Sun, L. Liu, B. Li, R. H. Kim and
J. M. Mathis
Louisiana State University Health Sciences
Center-Shreveport, Shreveport, LOUISIANA
Introduction: Virotherapy using oncolytic adenoviruses
(Ads) is an innovative approach to cancer therapy. The c-Met
receptor and its ligand, hepatocyte growth factor (HGF), are
involved in a wide array of neoplastic diseases, including
pancreatic cancer. We created a novel oncolytic adenovirus
by incorporating NK2, a competitive antagonist of the HGF/
c-Met association, into the Ad serotype 5 knob fiber. We
hypothesized that this new oncolytic Ad will result in effi-
cient viral transduction and cell killing in an array of human
pancreatic cancer cell lines.
Methods: Human pancreatic cancer lines CFPAC-1,
AsPC-1, and BxPC-3 were obtained from the American Type
Culture Collection. Efficiency of Ad infection in the cells was
determined using an vector construct expressing the green
fluorescence protein (GFP) marker in place of the E1A gene
(Ad5-RFP-FF-NK2) and quantified by flow cytometry.
Oncolytic activity in the pancreatic cancer cells was deter-
mined using the oncolytic Ad5-NK2-E1A by a crystal violet
staining method.
Results: C-Met was overexpressed in all three pancreatic
cancer cell lines. The oncolytic Ad5-NK2 was more efficient
in transducing pancreatic cancer cell lines as well as cell
killing than wild type adenoviruses (sample graphs below).
Conclusion: The novel recombinant oncolytic Ad5-NK2
efficiently transduced and killed human pancreatic cancer
cells. This novel construct represents a potential new therapy
against pancreatic cancer.
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O-H.03 NEOADJUVANT FOLFIRINOX
APPLICATION IN BORDERLINE
RESECTABLE PANCREATIC
ADENOCARCINOMA
A. Paniccia, B. Edil, R. Schulick, C. Gajdos, J. T. Byers,
C. Meguid and M. McCarter
University Of Colorado Hospital, Aurora, CO
Introduction: FOLFIRINOX has not been used extensively
in the neoadjuvant setting because of concerns with toxicity.
We evaluated our institutional experience with neoadjuvant
FOLFIRINOX in borderline resectable pancreas adenocarci-
noma (BRPAC). The primary endpoints were completion of
therapy to surgery, and R0 resection rate.
Methods: Retrospective analysis of patients with BRPAC
treated with neoadjuvant FOLFIRINOX. Two pancreatic sur-
geons reviewed all diagnostic and preoperative radiographic
imaging. Between August 2011 and June 2013, 17 patients
with BRPAC treated with neoadjuvant FOLFIRINOX were
identified.
Results: 94% of patients were able to undergo surgery. One
patient experienced toxicity. 10 pancreatic head lesions
(63%), 5 body lesions (31%) and 1 synchronous head and tail
lesion (6%). Abutment of PV/ SMV in 11 cases (69%), and
short segment PV encasement in 2 cases (19%). SMA abut-
ment in 1 case (6%), and concomitant abutment of the celiac
axis and PV in 1 case (6%). Patients received a median of 4
cycles of FOLFIRINOX. At a median interval of 10 weeks
from the first dose, 7 patients (44%) had partial radiologic
response and 9 patients (56%) had stable disease. There were
no cases of progression. Vascular resection was necessary in
7 cases (44%). All patients underwent margin negative resec-
tion (R0). Treatment effect in the pancreatic specimens
revealed poor or no response in 8 cases (50%), moderate
response in 4 cases (25%) and marked response in 4 cases
(25%).
Conclusion: Neoadjuvant FOLFIRINOX toxicity did not
prevent surgery and allowed a high rate of R0 resection.
O-H.04 PERIOPERATIVE RISK FACTORS
FOR DELAYED GASTRIC EMPTYING IN
PANCREATICODUODENECTOMY
J. R. Robinson2, P. Marincola3, J. Shelton2, N. Merchant1,
K. Idrees1 and A. Parikh1
1Vanderbilt University Medical Center, Nashville, TN;
2Vanderbilt University Medical Center, Nashville, TN;
3Vanderbilt University School Of Medicine , Nashville, TN
Introduction: Delayed gastric emptying (DGE) is a fre-
quent complication of pancreaticoduodenectomy (PD)
responsible for increased morbidity, prolonged hospital stay,
and readmission. We sought to further define the incidence of
DGE after PD based on the International Study Group of
Pancreatic Surgery (ISGPS) definition and evaluate associ-
ated perioperative risk factors.
Methods: 420 consecutive patients who underwent PD at
our tertiary referral center were reviewed. Using a stepwise
multivariate logistic regression model, perioperative factors
associated with the development of clinically significant
DGE defined by ISGPS grades B and C were assessed.
Results: Clinically significant DGE occurred in 24% of
patients (N = 98) with Grades B and C occurring at 13.5%
(N = 55) and 10.5% (N = 43), respectively. Grade B or C
DGE patients had significantly longer mean hospital stay (20
vs. 9 days, p < 0.001) and higher rate of 90-day readmission
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(32% vs. 18%, p = 0.004) than those without DGE. By
univariate analysis, white race, increasing ASA class,
BMI > 35, OR length >6 hrs, preoperative weight loss and
octreotide use were associated with increased risk of
DGE. By stepwise multivariable regression, BMI > 35
(OR = 3.42), OR length >6 hrs (OR = 2.97), preoperative
weight loss (OR = 2.05), and use of octreotide (OR = 2.33)
were independently associated with increased risk of DGE.
Conclusion: DGE remains a significant cause of morbidity,
increased hospital stay, and higher readmission rates after
PD. Our findings suggest patients with BMI > 35, preopera-
tive weight loss, or longer OR times be considered for
gastrostomy and/or jejunostomy tube placement and limited
octreotide use to decrease the potential risk and conse-
quences of DGE.
O-H.05 COST COMPARISON ANALYSIS
OF OPEN VS. LAPAROSCOPIC DISTAL
PANCREATECTOMY
D. R. Rutz1, M. H. Squires1, S. K. Maithel1,
J. M. Sarmiento2, J. W. Etra1, S. D. Perez2, W. Knechtle2,
K. Cardona1, M. C. Russell1, C. A. Staley1, J. F. Sweeney2
and D. A. Kooby1
1Department Of Surgery, Division Of Surgical Oncology,
Winship Cancer Institute, Emory University, Atlanta,
GEORGIA; 2Department Of General And Gastrointestinal
Surgery, Emory University, Atlanta, GEORGIA
Introduction: As compared with open distal pancreatec-
tomy (ODP), laparoscopic distal pancreatectomy (LDP)
carries fewer complications and shorter hospital stays for
selected patients, but cost data between the two approaches
are limited. We analyzed operative and hospital costs of both
approaches at our institution.
Methods: Records from all DPs from 1/2009–6/2013 were
reviewed and stratified by complexity (standard vs. high).
Patient factors and outcomes were recorded. Total variable
costs (TVC) were tabulated for each patient, and then by
category (e.g. “floor,” “OR,” “radiology,” etc . . .). Costs were
compared between LDP and ODP groups for index admis-
sions and any readmissions. Differences in means between
groups were compared via independent samples T-tests. Cat-
egorical variables were analyzed by chi-square test.
Results: Of 153 procedures, 115 were ‘standard’ complexity
(70 LDP, 45 ODP) and were analyzed. The LDP and ODP
groups had similar patient demographics and complication
rates (Table). TVC of the index admission was $3,418 less
per patient in the LDP group ($10,484 vs. $13,903,
p = 0.059). Although operating costs were significantly
greater in the LDP cohort ($5,756 vs. $4,900, p = 0.017), the
shorter hospitalization for the LDP group (5.2 vs. 7.7 days,
p = 0.009) resulted in lower overall cost. Total cost of index
hospitalization combined with readmission was significantly
less in the LDP group ($11,106 vs. $14,803, p = 0.05).
Conclusion: For appropriately selected patients, the
laparoscopic approach to distal pancreatectomy is more cost-
effective than the open approach. Increased OR cost associ-
ated with LDP is offset by the shorter hospitalization. These
data provide targets for further cost reduction.
O-H.06 FAILURE OF NARCOTIC WEAN
AFTER TOTAL PANCREATECTOMY
WITH ISLET AUTOTRANSPLANTATION
K. A. Morgan, S. M. Owczarski, H. Wang, W. Balliet,
J. J. Borckardt and D. B. Adams
Medical University Of South Carolina, Charleston, SC
Background: Pancreatectomy with islet autotransplantation
(TPIAT) is an effective means of pain relief in selected
patients with debilitating pain from chronic pancreatitis.
Patient selection remains challenging. Despite significant
improvements in quality of life, many patients continue to
require daily narcotic medication postoperatively. We sought
to identify predictive factors for success at postoperative
narcotic weaning.
Methods: A prospectively collected database of patients
undergoing TPIAT between March 2009 and March 2013
was reviewed, with attention to patient characteristics, daily
morphine equivalents, and quality of life (SF-12), from the
preoperative period and up to 36 months postoperative.
Results: 104 patients (81 women, age 41) underwent TPIAT
and had at least 6 months follow-up data. Mean physical
QOL (pQOL) improved from 27.3 preoperatively to 35.1
(p < 0.001) and mean mental health QOL (mhQOL)
improved from 38.4 preoperatively to 44.7 (p = 0.001) at last
postoperative follow-up (mean 1.7 years). Despite this, 27%
of patients (29/104) did not wean significantly their narcotic
requirement. Preoperative daily narcotic doses were
277 MEs (range 0–2518). Comparison of patients successful
at narcotic wean (SNW) with those who failed (FNW), dem-
onstrated they were similar in gender, age, disease duration,
and etiology. While preop pQOL was similarly poor (28.6 v
27.1), FNW patients had lower preoperative mhQOL (33.5 v
38.6 p = 0.05).
Conclusions: TPIAT results in significant improvements in
QOL, but narcotic weaning is more complex. Patients with
low preoperative mhQOL are less likely to wean narcotics
postoperatively. Behavioral psychology intervention should
be focused in this patient population.
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O-H.07 RISK FACTORS FOR
DEVELOPMENT OF STEATOSIS AND
STEATOHEPATITIS AFTER
PANCREATICODUODENECTOMY
L. K. Fonkoua, R. Tappouni, N. H. Bhayani, E. T. Kimchi,
K. F. Staveley-O’Carroll, J. T. Kaifi and N. J. Gusani
Program For Liver, Pancreas, & Foregut Tumors; Penn
State College Of Medicine, Hershey, PA
Introduction: A significant number of patients undergoing
pancreaticoduodenectomy (PD) develop Non-Alcoholic
Fatty Liver Disease (NAFLD) postoperatively, and some
patients even progress to Non-Alcoholic Steatohepatitis
(NASH). The etiology of these fatty changes in the liver after
PD remains unclear.
Methods: Patient demographics, operative procedures,
pathology, imaging, and perioperative clinical variables for
102 patients undergoing PD between 2002 and 2010 were
retrospectively examined, and the most influential risk
factors for development of postoperative liver steatosis were
identified by uni- and multivariate analyses.
Results: Of 102 patients who underwent PD, 21 (20.6%)
developed hepatic steatosis, as measured by a significant
change of liver-to-spleen attenuation ratio (L/S ratio) on
unenhanced computed tomography (CT) images during the
follow-up period. Overall, patient demographics, preopera-
tive findings, operation types, and final pathological findings
did not differ significantly between the steatosis patients and
the controls; however, the frequency of preoperative BMI
>30 was higher in the steatosis group (48% vs 19%,
p = 0.0098). In addition, this group had a lower proportion of
pancreatic ductal adenocarcinoma patients (24% vs 76%,
p = 0.0001) and a higher proportion of ampullary/duodenal
carcinomas (48% vs 7.4%, p = 0.003) compared to the no
steatosis group. A multivariate logistic regression analysis
identified pancreatic ductal adenocarcinoma (p = 0.005) and
postoperative chemoradiation therapy (p = 0.035) as inde-
pendent risk factors for the development of hepatic steatosis.
Conclusion: Postoperative hepatic steatosis occurs in
20.6% of patients after PD. Risk factors for development of
steatosis include pathologic subtype of pancreatic ductal
adenocarcinoma and receipt of adjuvant chemoradiation
therapy.
O-H.08 CASE CONTAMINATION
REPORTING IN HPB SURGERY: CAN A
SINGLE WORD CHANGE PUBLIC
PERCEPTION OF INSTITUTIONAL
PERFORMANCE?
P. J. Speicher, D. Nussbaum, J. E. Scarborough,
R. R. White, C. R. Mantyh, D. S. Tyler and B. M. Clary
Department Of Surgery, Durham, NC
Introduction: The drive to improve patient outcomes and
the inevitability of mandated public outcomes reporting
necessitate uniform reporting processes and accurate admin-
istrative databases. While conducting an internal QI process,
we identified non-uniformity within NSQIP in the reporting
of case contamination status in patients undergoing HPB
surgery and queried what the impact these inconsistencies
would have on quality metrics used as benchmarks for
comparison.
Methods: 27,376 hepatic and pancreatic resections were
identified from the 2005–2011 NSQIP Participant User Files.
The effect of case contamination status on postoperative SSI
rates was determined through stepwise forward multiple
logistic regression modeling. The impact of alternative case-
contamination reporting policies on observed : expected
ratios for SSI was then simulated for poor, average, and high
performing institutions.
Results: Significant heterogeneity in contamination status
reporting was present. For example, despite clear NSQIP
guidelines prompting at least “clean-contaminated” designa-
tion, 8% of all patients were coded as “clean”. Although
typically homogeneous in conduct, over 10% of
pancreaticoduodenectomy and partial hepatectomy (with
biliary/intestinal procedures) cases were classified as “con-
taminated” or “dirty” instead of “clean-contaminated”. Con-
taminated (AOR 1.39, p = 0.001) and dirty (AOR 1.42,
p = 0.02) cases were associated with higher odds of SSI,
while clean-contaminated were not (p = 0.99). O/E ratios
were highly sensitive to modest changes in the proportion
of HPB resections classified as “contaminated” or higher
(Table 1).
Conclusion: NSQIP SSI O : E ratios are easily modified by
institutional contamination classification policies. As institu-
tions work to improve outcomes and prepare for public
reporting, it is imperative that all adhere to consistent out-
comes reporting practices.
O-H.09 TARGETED INHIBITION
OF THE AKT PATHWAY IN
CHOLANGIOCARCINOMA BY MK2206
J. M. Wilson, S. Kunnimalaiyaan, M. Kunnimalaiyaan and
T. Gamblin
Medical College Of Wisconsin, Department Of Surgery,
Division Of Surgical Oncology, Milwaukee , WI
Introduction: Cholangiocarcinoma (CCA) is a rare disease
with limited effective treatment options. The PI3K/Akt
pathway represents an attractive therapeutic target due to its
frequent dysregulation in CCA. MK2206, an allosteric Akt
inhibitor, has been shown to reduce cellular proliferation in
other cancer types. We hypothesized that MK2206 mediated
inhibition of Akt in human CCA cells would impact cell
viability and sought to establish a dose and time correlate.
Methods: Human CCLP and SG231 CCA cell lines were
treated with 0–2 μM MK2206. MTT assay was used to
assess cellular viability at 96 hours. Expression levels of
apoptotic markers and cell cycle proteins were determined
via western blot.
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Results: CCLP viability was significantly reduced at
MK2206 concentrations of 0.5, 1, and 2 μM by approxi-
mately 44%, 53%, and 64% respectively (p < 0.01). SG231
also demonstrated significant reduction in viability of 32%,
32%, and 42% respectively for the same treatment concen-
trations (p < 0.05). Western analysis revealed a strong
decrease in phosphorylated AKTSer473, while phosphorylated
AKTThr308 remained unchanged in both cell lines. In addition,
cleaved PARP expression was increased while pro-caspase 3
and 9 expression was reduced. Interestingly, survivin expres-
sion increased with treatment in both cell lines.
Conclusion: Our study clearly demonstrates that by block-
ing phosphorylation of Akt at serine 473, CCA cellular
growth is reduced. This growth suppression is mediated via
apoptosis induction. Importantly, the concentrations needed
for growth reduction in CCA are less than those needed in
other cancer types. It is anticipated that these concentrations
could be achieved in vivo with limited toxicity.
O-H.10 ARE GENERAL SURGERY
RESIDENTS ADEQUATELY PREPARED
FOR HEPATOPANCREATICOBILIARY
(HPB) FELLOWSHIPS? QUESTIONNAIRE
BASED STUDY
H. Osman1, J. Parikh2, S. Patel1 and D. Jeyarajah1
1Methodist Dallas Medical Center, Dallas, TX; 2Indiana
University Hospital, Indianapolis, IN
Objectives: HPB fellowship addresses organ diseases that
are not heavily covered during residency. Moreover, it is a
technically demanding field. We aim to identify challenges
that HPB fellows have experienced during the initial part of
their HPB training.
Methods: An online questionnaire was designed and
distributed electronically to all HPB fellows (n = 20) in
fellowship council accredited programs in the academic year
2012–2013. Responses were then analyzed.
Results: Response rate was 45% (n = 9). Prior to their fel-
lowship, 55.6% were in surgical residency, 33.3% were in
another fellowships, while 1 fellow (11.1%) was in general
surgery practice. 77.8% were graduates of university based
residency programs. 77–88% felt comfortable performing
basic general surgery procedures independently at the end of
residency training. When uncomfortable performing basic or
advanced surgical procedures, 77.7% cited case volume and
lack of autonomy during residency as reasons. 44.4% cited
inability to adequately perform preoperative workup for
general surgical diseases as their biggest fear entering prac-
tice. 77.8–88.9% felt adequately prepared handling benign
and malignant HPB diseases at the beginning of fellowship.
Minimal invasive surgery and transplant rotations were cited
as non-HPB rotations more likely to prepare residents for
their upcoming HPB fellowship.
Conclusion: HPB fellows felt overall to be adequately pre-
pared for their fellowship. Case volume and intraoperative
autonomy are the 2 biggest reason when fellows felt insuffi-
ciently prepared. General surgery residents who plan on pur-
suing HPB fellowship may benefit from spending extra
rotation on certain subspecialties in addition to focus on
preoperative workup and management.
O-H.11 PORTAL VENOUS SYSTEM
DECOMPRESSIVE PROCEDURES
DURING PANCREATIC RESECTION:
PERIOPERATIVE AND LONG-TERM
OUTCOMES
M. J. Truty1, R. M. Thomas3, J. E. Lee2, M. H. Katz2 and
J. B. Fleming2
1Mayo Clinic College Of Medicine, Rochester, MN;
2University Of Texas, MD Anderson Cancer Center,
Houston, TX; 3University Of Florida College Of Medicine,
Gainseville, FL
Background: Sinistral portal hypertension may occur fol-
lowing splenic vein ligation and SMV/PV resection during
pancreatectomy in the absence of adequate gastro-splenic
collaterals. Varices associated with occluded SMV/PV
increase risk of intraoperative hemorrhage due to mesenteric
venous hypertension. Distal splenorenal shunts (DSRS) and
temporary mesocaval shunts (MCS) can prevent such respec-
tive complications.
Design: Patients that required portal decompressive pro-
cedures during pancreatectomy were identified. Clinico-
pathologic outcomes, shunt patency, and postoperative
gastro-splenic complications were reviewed.
Results: Twenty-one decompressive procedures were per-
formed in 18 patients who required SMV/PV reconstruction.
16 patients had pancreatic adenocarcinoma. SMV/PV recon-
struction was performed primarily in 7 (39%) patients and
with interpositional grafting in 11 (61%) patients. 4 (24%)
patients required simultaneous hepatic arterial resection/
reconstruction. The R0 resection rate was 94%. DSRS was
constructed in 16 patients and 2 patients underwent
splenoportal anastomoses. Temporary MCS was performed
concomitantly in 3 patients. Mean (median) operative time,
EBL, and LOS were 664 (643) min, 1111 (900) ml, and 13
(11) days, respectively. Major complications occurred in 5
(28%) patients. One patient developed bleeding gastropathy
from acute sinistral hypertension due to splenoportal
anastomotic thrombosis requiring emergency splenectomy.
Postoperative imaging revealed mean (median) shunt
patency of 12.8 (5.7) months. No patients developed late
hypersplenism.
Conclusion: Portal decompressive procedures during pan-
createctomy are safe and may minimize intraoperative bleed-
ing and the development of early/late sinistral hypertension
after splenic vein ligation for SMV/PV reconstruction. DSRS
may be preferable to splenoportal anastomoses due to throm-
bosis risk. The excellent early patency may minimize acute
complications until appropriate collaterals develop.
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O-H.12 COST-EFFECTIVENESS AFTER
PANCREATICODUODENECTOMY:
BOLSTERING THE VOLUME
ARGUMENT
J. M. Sutton, G. C. Wilson, K. Wima, R. C. Quillin,
I. M. Paquette, D. J. Hanseman, J. J. Sussman,
M. J. Edwards, S. A. Ahmad, S. A. Shah and D. E. Abbott
Department Of Surgery, University Of Cincinnati Medical
Center, Cincinnati, OH
Background: The cost implication of variability in pancre-
atic surgery is not well described. We hypothesized that for
pancreaticoduodenectomy (PD), lower volume centers dem-
onstrate worse perioperative outcomes at higher costs.
Methods: 9,883 patients undergoing PD from 2009–2011
were identified from the University Healthsystems Consor-
tium database and stratified into quintiles by hospital and
surgeon volume. A decision analytic model was constructed
to assess cost-effectiveness. Costs were based on Medicare
cost : charge ratios and included readmission costs when
applicable.
Results: When both index and readmission costs were con-
sidered, the median per-patient cost at the lowest-volume
centers was $23,005, or 10.9% ($2,263 per case) more than at
the highest-volume center. Additionally, the lowest volume
centers demonstrated inferior perioperative outcomes with a
higher median overall length of stay (11 vs. 8 days,
p < 0.001), higher perioperative mortality rate (3.5% vs.
1.3%, p < 0.001), and higher 30-day readmission rate (20%
vs. 16%, p = 0.003) compared to the highest-volume centers.
Similar to hospitals, low volume surgeons had higher
perioperative mortality (3.1% vs. 1.2%; p = 0.004) and read-
mission rates (19% vs. 16%; p = 0.008). One-way sensitivity
analyses adjusting for perioperative mortality (1.3% at all
centers) and readmission rates (16% at all centers) did not
materially change the cost-effectiveness analysis. Differ-
ences in cost were largely recognized in the index admission;
readmission costs were similar across quintiles.
Conclusions: For PD, lower volume centers have higher
perioperative mortality, 30-day readmission rates, longer
LOS and 10.9% higher cost per patient. Performance of PD
at higher volume centers can lead to both better outcomes
and substantial cost savings.
O-H.13 PANCREATICODUODENECTOMY
IN FLORIDA: DO 20 YEAR TRENDS
DOCUMENT SALUTARY BENEFITS OF
CENTRALIZATION OF CARE?
T. W. Wood, S. B. Ross, A. E. Smart, C. E. Ryan,
P. B. Sukharamwala and A. S. Rosemurgy
Florida Hospital Tampa, Tampa, FL
Introduction: Concentration of care has been promoted as
fostering superior outcomes. This study was undertaken to
determine if concentration of care is occurring in Florida for
pancreaticoduodenectomy, and if so, is it having a salutary
effect.
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Methods: The data for pancreaticoduodenectomy were
obtained from the Florida Agency for Health Care Adminis-
tration for three 3-year periods:1992–1994, 2001–2003,
2010–2012; data were sorted by surgeon volume of
pancreaticoduodenectomy during these periods and corre-
lated to postoperative length of stay (LOS), in-hospital mor-
tality, and hospital charges (adjusted to 2012 dollars).
Results: Relative to 1992–1994, in 2010–2012 46% fewer
surgeons undertook 115% more pancreaticoduodenectomies
with significant reductions in LOS and in-hospital mortality,
and higher charges (p < 0.001 for each) (Figure). In 1992–
1994, 62% of pancreaticoduodenectomies were undertaken
by surgeons undertaking ≤1 per year; this fell to 13% in
2010–2012. Similarly, from 1992–1994 to 2010–2012 there
was an 18-fold increase in the number of pancreatico-
duodenectomies by surgeons undertaking ≥12 per year
(n = 45 to n = 806, respectively). During 2010–2012, the
more frequently surgeons undertook pancreaticoduo-
denectomy, the shorter LOS, the lower in-hospital mortality,
the greater likelihood of discharge home, and the lower hos-
pital charges (p < 0.03 for each)
Conclusion: Over the last 20 years concentration of care has
occurred in Florida with substantially fewer surgeons under-
taking many more pancreaticoduodenectomies with dramatic
improvements in LOS and in-hospital mortality, albeit with
increased hospital charges. During 2010–2012, busiest sur-
geons got the best results, since the frequency with which
surgeons undertook pancreaticoduodenectomy favorably
impacted LOS, in-hospital mortality, the likelihood of dis-
charge home, and hospital charges.
O-H.14 AJCC STAGING FOR RESECTED
HILAR CHOLANGIOCARCINOMA: 7TH
EDITION BETTER THAN 6TH, BUT NOT
AN INDEPENDENT PROGNOSTIC
FACTOR
B. Groot Koerkamp1, J. K. Wiggers2, P. J. Allen1,
O. R. Busch2, M. I. D’Angelica1, R. P. Dematteo1,
Y. Fong1, D. J. Gouma2, T. P. Kingham1, T. M. Van Gulik2
and W. R. Jarnagin1
1Memorial Sloan-Kettering Cancer Center, New York, NEW
YORK; 2Academic Medical Center Amsterdam, Amsterdam,
NOORD-HOLLAND
Background: This study evaluates the prognostic value of
the 6th and 7th edition of the AJCC staging system for patients
with resected hilar cholangiocarcinoma (HCCA).
Methods: Patients with HCCA resected between 1991 and
2012 were identified from prospective databases from two
institutions. Kaplan-Meier median overall survival was com-
pared between stage groups with the logrank test.
Multivariable Cox-proportional hazards modelling was used
to evaluate the independent prognostic value of the two
staging systems.
Results: 302 patients were analyzed. The median overall
survival was 38 months and 5-year survival was 37%. In the
7th edition 64% of patients were upstaged from the 6th edition.
Both staging schemes were strong prognostic factors on
univariate analysis: p = 0.0007 (6th) and P < 0.00001 (7th).
The 7th edition more effectively stratified survival by stage:
median survival for stage 0 (carcinoma in situ) was 80
months; stage I (confined to bile duct) 90 months; stage II
(beyond bile duct) 47 months; stage III (node positive) 23
months; and stage IV (invasion main portal vein, common
hepatic artery, second-order bile ducts, or distant metastasis)
24 months. Neither the 6th nor the 7th editions were independ-
ent predictors of survival in a multivariable model including
margin status, nodal status, tumor differentiation, and
perineural invasion. The AJCC staging (7th edition) was an
independent prognostic factor only for patients with an R0
resection.
Conclusion: The 7th edition of the AJCC staging system for
HCCA improves stratification, but its prognostic value is lost
in the face of other, more potent variables.
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O-H.15 HIGH-VOLUME SURGEONS
VERSUS HIGH-VOLUME HOSPITALS:
ARE BEST OUTCOMES MORE DUE TO
WHO OR WHERE?
S. B. Ross1, A. N. Igartua1, M. DeGori1, A. F. Teta1,
K. Luberice1, P. G. Toomey2, P. B. Sukharamwala1 and
A. S. Rosemurgy1
1Florida Hospital Tampa, Tampa, FL; 2University Of South
Florida Department Of Surgery, Tampa, FL
Introduction: High-volume hospitals are purported to
provide ‘best’ outcomes. High-volume hospitals and high-
volume surgeons are inextricably related. We undertook
this study to evaluate the outcomes after pancreaticoduo-
denectomy when high-volume surgeons relocate to a low-
volume hospital.
Methods: Outcomes after the last 50 pancreaticoduo-
denectomies at a high-volume hospital in 2012 were
compared to the outcomes after the first 50 pancreaticoduo-
denectomies undertaken at a low-volume (i.e., no pancrea-
ticoduodenectomies in >5 years) hospital in 2012–13. Data
are presented as median (mean ± SD).
Results: Patients undergoing pancreaticoduodenectomies at
a high-volume vs. a low-volume hospital were not different
relative to sex and age (Table). Patients operated upon at the
low-volume hospital had lower ASA class, had shorter opera-
tions with less blood loss, spent less time in the ICU, and had
shorter length of stay (p < 0.05 for each, Table); 30-day mor-
tality and 30-day readmission rates were not different
(Table).
Conclusion: The salutary benefits of being a high-volume
hospital for pancreaticoduodenectomy are transferred to a
low-volume hospital when high-volume surgeons relocate.
The ‘best’ outcomes associated with high-volume hospitals
may be primarily due to the high-volume surgeons who work
there, and the ‘best’ results follow the high-volume surgeons.
The ‘best’ results seem to be related more to who does the
pancreaticoduodenectomy rather than where the pancreatico-
duodenectomy is undertaken.
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OP-II.01 EXPRESSION OF FATTY ACID
BINDING PROTEINS IN A MOUSE
MODEL OF OBESITY-ASSOCIATED HCC
K. J. Thompson, S. S. Nazari, D. A. Iannitti,
I. H. McKillop and D. Sindram
Carolinas Medical Center, HPB Surgery, Charlotte, NC
HCC is the 3rd leading cause of cancer-related mortality. Risk
factors for HCC include viral hepatitis and chronic alcohol
consumption, with obesity emerging as an important risk
factor. The aim of this study was to investigate expression of
fatty acid binding proteins (FABPs) as potential biomarkers
of obesity-associated HCC. C57BL/6 mice were injected
with vehicle (Veh) or diethylnitrosamine (DEN; 5 mg/kg) at
21–24 d. At 5 wks, mice were placed on control diet (CD;
10% kcal%/fat) or high fat diet (HFD; 60% kcal%/fat). At
42 wks livers examined for gross tumor incidence and his-
tology performed. To assess FABP expression, RT-qPCR and
immunoblots were performed. Animals on HFD-Veh formed
large tumors in 30% of animals, an effect exacerbated by
DEN administration (90%), compared to small tumors in
60% in CD-DEN. Expression of FABP1 was upregulated in
CD-DEN and HFD-DEN compared to Veh-injected animals.
FABP2 was unchanged between CD-Veh and –DEN and
HFD-Veh animals. However; there was a 2-fold down regu-
lation of FABP2 in livers of HFD-DEN non-tumor tissue
(NT) compared to HFD-DEN tumor (T) tissue. There was
∼1000-fold upregulation of FABP4 in HFD animals com-
pared to CD animals, an effect exacerbated in DEN-injected
animals. FABP5 expression was downregulated in HFD-Veh
and HFD-DEN-NT tissue; however, HFD-DEN-T tissue
expressed 3-fold higher levels. FABPs are dysregulated in
obesity-associated HCC. Interestingly, there is a reciprocal
relationship between expression of FABPs 1, 2 and 5 in
tumor tissue from HFD-DEN mouse livers compared to NT
liver tissue. These findings suggest FABPs may be
biomarkers for obesity-associated HCCs.
OP-II.02 SURVIVAL FOLLOWING
MULTIDISCIPLINARY MANAGEMENT
OF EXTENSIVE COLORECTAL LIVER
METASTASES
J. Pasko, J. Wagner, O. Lafi, B. Sheppard, S. Orloff,
G. Vaccaro, C. Lopez and K. G. Billingsley
Oregon Health And Sciences University, Portland , OR
Introduction: Developments in surgical technique and uti-
lization of peri-operative oxaliplatin based chemotherapy
have provided the opportunity of resection to patients with
extensive colorectal liver metastases (CRLM). The aim of
this study is to assess survival and disease recurrence follow-
ing resection for patients with advanced CRLM.
Methods: This is a single institution retrospective review of
patients with colorectal liver metastases from June 2003 to
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